Leonard Zehr, Author at BioTuesdays

Feature

Obalon developing retail strategy for its weight loss solution: a swallowable, gas-filled intragastric balloon

Obalon Therapeutics (NASDAQ:OBLN) is pivoting its business model to a retail strategy of company-managed clinics to deliver its Obalon Balloon System, a weight loss solution that is the first and only swallowable, gas...

March 17, 2020

Feature

Diabeloop bringing innovation to Type 1 diabetes patients

Closely-held Diabeloop of Grenoble, France has developed an external Type 1 diabetes management system, known as DBLG1, that connects three components: a continuous glucose monitor, a patch-like insulin pump and an...

March 10, 2020

Feature

Anixa Biosciences harnessing interactions between tumors and the immune system

Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...

March 3, 2020

Feature

Ocugen developing therapies for rare and underserved eye diseases

Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...

February 25, 2020

Feature

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...

February 18, 2020

Feature

Stereotaxis focused on next generation robotic innovation in interventional medicine

Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping stone to improve patient care...

February 4, 2020

Feature

Liminal BioSciences making headway in strategic transformation

Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics. “This is a refresh of...

January 21, 2020

Feature

BriaCell breast cancer program ready for partnering

BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune checkpoint inhibitors such as...

January 7, 2020

Feature

Kane Biotech completes 12-month transformation; ready for robust growth

Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...

December 10, 2019

Feature

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Closely-held Squarex will be seeking an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 as a steppingstone for pivotal testing of its SQX770 topical treatment for the prevention of recurrent cold sores...

December 3, 2019

Author - Leonard Zehr

Obalon developing retail strategy for its weight loss solution: a swallowable, gas-filled intragastric balloon

Diabeloop bringing innovation to Type 1 diabetes patients

Anixa Biosciences harnessing interactions between tumors and the immune system

Ocugen developing therapies for rare and underserved eye diseases

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Stereotaxis focused on next generation robotic innovation in interventional medicine

Liminal BioSciences making headway in strategic transformation

BriaCell breast cancer program ready for partnering

Kane Biotech completes 12-month transformation; ready for robust growth

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Subscribe